688091.SHG Shanghai Yizhong Pharmaceutical Co Ltd
- Market cap
- CNY 7.66B
- P/E
- 109.0x
- P/B
- 4.91x
- ROE
- 5.1%
- Dividend yield
- 0.00%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is 688091.SHG undervalued?
Graham numberThe Graham number of Shanghai Yizhong Pharmaceutical Co Ltd cannot be estimated reliably (the estimate is too far from the market price).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Shanghai Yizhong Pharmaceutical Co Ltd fundamental analysis
No fundamental analysis for Shanghai Yizhong Pharmaceutical Co Ltd yet.
Shanghai Yizhong Pharmaceutical Co Ltd stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Shanghai Yizhong Pharmaceutical Co Ltd
Shanghai Yizhong Pharmaceutical Co., Ltd. engages in the research and development of anti-tumor drugs and related products in China. The company offers paclitaxel polymer micelles for injection for the treatment of non-small cell lung cancer, as well as various types of cancer, including esophageal cancer, gastric cancer, nasopharyngeal carcinoma, pancreatic cancer, breast cancer, and gynecological tumors. Shanghai Yizhong Pharmaceutical Co., Ltd. was founded in 2009 and is …
Full company profileShanghai Yizhong Pharmaceutical Co Ltd financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Shanghai Yizhong Pharmaceutical Co Ltd annual financial statements (CNY; K = thousand, M = million, B = billion, T = trillion)
| Item | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||||
| Revenue | - | - | 0.00 | 0.00 | 4.08M | 236M | 360M | 174M | 317M | 337M |
| Gross Profit | - | -5.52M | -5.98M | -7.13M | 3.78M | 219M | 337M | 160M | 317M | 288M |
| Operating Income | -10.1M | -12.6M | -315M | -21.8M | -9.28M | 152M | 195M | 9.54M | 62.1M | 58.5M |
| EBITDA | -5.72M | -8.04M | -310M | -15.7M | -2.10M | 156M | 195M | 16.8M | 72.1M | 70.6M |
| Net Income | -10.1M | -12.6M | -315M | -21.8M | -4.00M | 143M | 162M | 6.98M | 64.1M | 74.4M |
| EPS | -0.08 | -0.09 | -2.26 | -0.14 | -0.03 | 0.69 | 1.02 | 0.03 | 0.31 | 0.36 |
| Balance Sheet | ||||||||||
| Total Assets | 214M | 229M | 278M | 259M | 1.20B | 1.35B | 1.57B | 1.45B | 1.53B | 1.58B |
| Total Liabilities | 16.2M | 17.1M | 12.3M | 15.3M | 25.0M | 35.4M | 109M | 43.0M | 96.8M | 119M |
| Shareholders' Equity | 198M | 212M | 265M | 244M | 1.18B | 1.32B | 1.46B | 1.41B | 1.43B | 1.46B |
| Cash & Short-term Investments | 2.71M | 3.17M | 131M | 51.1M | 953M | 1.13B | 1.24B | 666M | 43.9M | 387M |
| Total Debt | - | - | - | 3.25M | 16.8M | - | 44.0M | - | - | - |
| Cash Flow | ||||||||||
| Operating Cash Flow | -11.5M | -10.7M | -23.9M | -20.2M | -48.8M | 111M | 86.6M | 39.4M | -19.4M | - |
| Capital Expenditure | 1.13M | 3.46M | 47.6M | 5.00M | 3.14M | 35.9M | 8.78M | 80.0M | 130M | 47.3M |
| Free Cash Flow | -12.6M | -14.1M | -71.5M | -25.2M | -51.9M | 74.9M | 77.8M | -40.6M | -149M | 5.00M |
| Ratios | ||||||||||
| ROE | -5.1% | -5.9% | -118.8% | -9.0% | -0.3% | 10.8% | 11.0% | 0.5% | 4.5% | 5.1% |
| ROA | -4.7% | -5.5% | -113.5% | -8.4% | -0.3% | 10.5% | 10.3% | 0.5% | 4.2% | 4.7% |
| Net Profit Margin | - | - | - | - | -98.0% | 60.5% | 44.8% | 4.0% | 20.2% | 22.0% |
| Debt to Equity | - | - | - | 0.01x | 0.01x | - | 0.03x | - | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Shanghai Yizhong Pharmaceutical Co Ltd dividends
- Dividend yield
- 0.00%
- Forward dividend
- -
- Payout ratio
- 0.1%
- Ex-dividend date
- May 17, 2024
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | CNY 73.8K | 0.00 | 0.1% |
| 2024 | CNY 49.8M | 0.21 | 713.9% |
| 2023 | CNY 43.4M | 0.27 | 26.9% |
| 2022 | CNY 491K | 0.00 | 0.3% |
| 2021 | CNY 589K | 0.00 | - |
| 2020 | - | - | - |
| 2019 | - | - | - |
| 2018 | - | - | - |
| 2017 | - | - | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 1.3:1 on May 17, 2024.
Who owns Shanghai Yizhong Pharmaceutical Co Ltd
- Insiders 52.53%
- Institutions 2.99%
- Public & others 44.48%
- Shares outstanding 207M
- Free float 104M
Shanghai Yizhong Pharmaceutical Co Ltd company profile
- Company name
- Shanghai Yizhong Pharmaceutical Co Ltd
- Ticker
- 688091.SHG
- ISIN
- CNE1000050F4
- Exchange
- Shanghai Stock Exchange
- Sector
- Healthcare
- Industry
- Pharmaceuticals
- Employees
- 457
- Fiscal year end
- December
- Address
- No.79 Renqi Road, Shanghai, China, 201401
- Phone
- 86 21 3719 0005
- Website
- yizhongpharma.com
About Shanghai Yizhong Pharmaceutical Co Ltd
Shanghai Yizhong Pharmaceutical Co., Ltd. engages in the research and development of anti-tumor drugs and related products in China. The company offers paclitaxel polymer micelles for injection for the treatment of non-small cell lung cancer, as well as various types of cancer, including esophageal cancer, gastric cancer, nasopharyngeal carcinoma, pancreatic cancer, breast cancer, and gynecological tumors. Shanghai Yizhong Pharmaceutical Co., Ltd. was founded in 2009 and is headquartered in Shanghai, China.
Shanghai Yizhong Pharmaceutical Co Ltd management
6- Mr. Jingsong ZhouChairman & GM · born 1968
- Mr. Duan LiDeputy GM & Director · born 1940
- Ms. Jing SunDeputy GM & Director · born 1977
- Mr. Zhou FangBoard Secretary · born 1988
- Mr. Wenming ZhangDeputy General Manager · born 1984
- Tian RuanAccounting Supervisor